Display Settings:
Send to:
See comment in PubMed Commons below
Eur J Cardiothorac Surg. 2014 Apr;45(4):e110-7. doi: 10.1093/ejcts/ezt623. Epub 2014 Jan 14.
Biostability, durability and calcification of cryopreserved human pericardium after rapid glutaraldehyde-stabilization versus multistep ADAPT(R) treatment in a subcutaneous rat model.
Neethling W1, Brizard C, Firth L, Glancy R.
Author information
Abstract
- 1Department of Cardiothoracic Surgery, Fremantle Heart Institute, Fremantle Hospital and School of Surgery, University of Western Australia, Fremantle, WA, Australia.
OBJECTIVES:
Autologous pericardium rapidly fixed with glutaraldehyde (GA) in theatre is considered in many cardiac surgery centres the best material currently available for intracardiac, valvular or vascular repair. Implanted non-fixed autologous tissues suffer rapid degeneration, shrinkage and absorption whereas standard xenotypic fixed tissues cause local cytotoxicity and calcification. In the present study, using a subcutaneous rat model, we tested the biostability, durability and calcification potential of four different pericardium patches treated with GA and relevant to current clinical practice.
METHODS:
Pericardium samples were divided into four groups according to the method of treatment. Group I consisted of bovine pericardium (BP) fixed with 0.6% GA (control), Group II cryopreserved human pericardium (CHP) rapidly fixed with 0.6% GA for 4 min and detoxified with MgCl2, Group III CHP treated with the multistep ADAPT(®) process (delipidized, decellularized with Tx-100, deoxycholate, IgePal CA-630 and denucleased, fixed in 0.05% monomeric GA and detoxified) and Group IV BP treated with the multistep ADAPT(®) process (CardioCel(®)). Biostability was determined by shrinkage temperature which measures the degree of cross-linking, and durability assessed by resistance to a mixture of proteinases (pronase digestion). Treated pericardium samples (n = 10 in each of Groups I-IV) were implanted in the subcutaneous rat model for 8 and 16 weeks, followed by histology and calcium analysis (atomic absorption spectrophotometry).
RESULTS:
The biostability and the durability of both CHP and BP after the multistep ADAPT(®) treatment remained stable without any microscopic calcification. Extractable calcium levels of CHP were significantly (P < 0.01) reduced in Group II (1.89 ± 0.77 μg Ca/mg tissue) compared with Group I (64.37 ± 6.25 μg/mg) after 8 weeks. Calcification of CHP (Group III) and BP (Group IV) after the multistep ADAPT(®) treatment was significantly reduced (1.43 ± 0.48 µg/mg and 0.75 ± 0.10 μg/mg, respectively) compared with Group I (282.52 ± 18.26 μg/mg) and the rapidly treated CHP in Group II (11.32 ± 3.21 μg/mg) after 16 weeks.
CONCLUSIONS:
Improved biostability and durability with reduced calcification of tissues after the multistep ADAPT(®) tissue treatment suggest improved alternative substitutes to autologous pericardium.
KEYWORDS:
Calcification; Glutaraldehyde; Pericardium (bovine); Pericardium (human)
- Forums
- ASX - By Stock
- AVR
- abstract
abstract
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$23.48 |
Change
0.280(1.21%) |
Mkt cap ! $424.8M |
Open | High | Low | Value | Volume |
$23.50 | $23.55 | $23.15 | $347.1K | 14.83K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $23.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$23.48 | 954 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 23.000 |
3 | 4200 | 22.500 |
1 | 426 | 22.400 |
1 | 15 | 22.310 |
1 | 800 | 22.300 |
Price($) | Vol. | No. |
---|---|---|
23.550 | 400 | 1 |
23.690 | 400 | 1 |
23.750 | 240 | 1 |
23.940 | 160 | 1 |
24.110 | 222 | 1 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
$23.43 |
  |
Change
0.280 ( 1.87 %) |
|||
Open | High | Low | Volume | ||
$23.47 | $23.47 | $23.25 | 161 | ||
Last updated 15.35pm 28/03/2024 ? |
Featured News
AVR (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online